Nanobotmodels Company presents vision of modern drug delivery methods using DNA-origami nanoparticles. In animation you can see cancer therapy using doxorubicin, delivered by nanomedicine methods. You can watch detailed information about this animation on our webpage http://www.nanobotmedical.com/ Follow us on Facebook https://www.facebook.com/Nanobot.Medi... Follow us on LinkedIN https://www.linkedin.com/company/nano... Follow us on Twitter https://twitter.com/Nanobot_Studio Follow us on Instagram https://www.instagram.com/nanobot_med... #medicine #health #biology #science #oncology #gene #chemistry #3danimation #medschool #pharmacy #pharmacology #education #molecule #cell #molecule #pharma #sciart #visualscience #sciart #ScientificCommunication #3D #Art #Animation #pharma #Medical #medicalanimation #medicalillustration #raredisease #cgi #patienteducation #Alzheimer #microbiology #lbrain #neuroscience #brain #nanotechnology #cell #microbiology #cells #lipid #nanobot #nanobotmedical #nanobotstudio #gastroenterology
Views: 162914 Nanobot Medical Animation Studio
This animation describes the latest research developments in nanoparticle-based cancer therapies. It explores how the technology can be used to specifically target cancer cells over healthy cells and how scientists can exploit the natural processes of cells to deliver the drug inside the cell where it is needed for its cancer-killing effect. This animation was created by the 3D Visualisation Aesthetics Lab (UNSW, Sydney, Australia) as part of the research activities of the ARC Centre of Excellence in Bio-Nano Science and Technology. For more information please visit http://www.bionano.org.au/ To learn about other projects at 3DVAL, please visit https://www.artdesign.unsw.edu.au/3DVAL
Views: 2888 3D Visualisation Aesthetics Lab UNSW
A short animation outlining the fundamentals of targeted nanomedicine for cancer therapy, one of our group's primary research focuses. For more information, see http://nanomedicine.uwaterloo.ca © 2010 University of Waterloo Frank Gu Research Group Waterloo Institute for Nanotechnology Department of Chemical Engineering
Views: 278762 FGRGAnimation
Getting sufficient therapeutic drugs to the precise disease cell would reduce the amount of medication required; reduce side effects; and enhance treatment. Mabe explores the use of nano-particles for this purpose. Taylor is a doctoral student in the NC A&T/UNC Greensboro Joint School of Nanoscience and Nanoengineering in Greensboro NC. His interests are in the delivery of medicines through nano-particles to increase medication effectiveness and reduce side effects. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 15984 TEDx Talks
A new cancer treatment shrinks every kind of tumor it's been tested on. The Stanford Medical Center team has so far only tested the antibody on human cancer cells in petri dishes and in mice, but the results have been impressive: 10 out of the 10 tumors in mice shrank and in nine of the 10 mice, the cancer did not spread to their lymph nodes. Read the full story here: http://www.medicaldaily.com/articles/14434/20130328/cancer-treatment-cd47-miracle-bullet-breast-colon-bladder-antibody-eat-macrophage-immune.htm Subscribe to The Daily Conversation http://bit.ly/WZnLnd Join the conversation on Facebook http://www.facebook.com/thedailyconversation Add TDC to your circles on Google+ https://plus.google.com/100134925804523235350/posts Follow The Daily Conversation on Twitter http://www.twitter.com/thedailyconvo Videos used: Cancer Research UK http://www.youtube.com/watch?v=jWuyPi_nuJE normal mice.mpg http://www.youtube.com/watch?v=tcmyFj9DALI CD47 Antibody treatment shrinks or eliminates human cancer tumors in mice http://www.youtube.com/watch?v=EyGWZbmjeR0 3D Medical Animation - What is Cancer? http://www.youtube.com/watch?v=LEpTTolebqo Diabetes in Lab Mice Reversed with Natural Compound http://www.youtube.com/watch?v=0TlQWPg0NBk Images used: Petri dish http://www.flickr.com/photos/nathanreading/6751931965/lightbox/ Cell Culture http://www.flickr.com/photos/kaibara/3075268200/lightbox/ Mouse http://www.flickr.com/photos/dullhunk/7095792663/lightbox/ A new cancer-fighting drug has successfully shrunk every tumor its been tested on. This is a potentially huge breakthrough in the fight to cure cancer. The amazing work was done by a team at the Stanford University Medical Center that piggybacked on the knowledge that people with cancer have a lot more of these surface markers, called CD47, that say to the immune system, "don't eat me", essentially protecting bad cancer cells from being killed off. So they designed an antibody to shut these CD-47s up and introduced it into human cancer cells - not into humans directly yet, but in cells they took from humans and put in petri dishes and lab mice, and it worked: they found that when a variety of tumors, ranging from breast to brain, were hit with the antibody treatment, the CD47s were blocked, resulting in shrinking tumors, and a stopping of the spread of cancer. It worked in 10 out of the 10 mice they tested it on. This is so good, so groundbreaking, the team is now working with a $20 million grant to move from mouse trials to safety tests in humans. Now these results are maybe the most exciting ever in the history of cancer research, but there's still a ton of work to do. The microenvironment of a tumor interacting with the rest of the human body is way more complicated than treating a transplanted tumor in a mouse or one that's just lying in a petri dish. Tumors in humans could have additional immune suppressing effects that scientists will have to overcome and the antibody treatment used in this study could also create unknown side effects on the rest of the body. But that said, this story makes it seems like the fight to cure cancer is becoming more winnable by the day.
Views: 16827 The Daily Conversation
Treating cancer requires aggressive but targeted therapy. Some cancer drugs are too toxic because they damage healthy cells as well as tumor cells. So researchers are trying to develop ways to make sure drugs only target the right cells. One solution is to attach drugs to antibodies specific to a protein expressed on tumour cells. These drugs are called antibody-drug conjugates (ADCs). More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor. In this 3D animation, produced by Nature Biotechnology, we hear about these challenges and the ways ADCs target cells. This content is editorially independent of sponsors. Animation by Nucleus Inc.. www.nucleuscatalog.com/home
Views: 22227 nature video
https://www.youtube.com/playlist?list=PLvu6n-GsGFsYNp-TFHeYOrB_bpaYYrjHM NanoGuard Pharmaceuticals (NG) introduces a gold nanoparticle-based anti-cancer drug delivery system for clinicians and researchers to combat hard-to-reach and inoperable cancers. Nano-sized structured, our product reaches cancers with enhanced accumulation and causes heat-related tumor ablation via infrared excitation. Non-toxic, it can differentiate tumors from normal tissues even 48-hours post-injection. The technology is owned by National Institute of Biomedical Imaging and Bioengineering. Currently the product faces competition from liposomes, polymers, gels, and sprays which all can exhibit similar functions of delivering anti-drug medicine. Around 15% of market specializes in nanoparticle-based delivery system. Thus, the market is considered very competitive. However, the product has competitive advantages as a versatile cancer treatment method with unparalleled specifications. The overall market for cancer treatment is expected to value at USD 80 Billion with sustained double-digit growth rate. It is believed that penetrating into developed countries such as the US and EU, where the demand for high-end cancer treatment is high, can yield a tremendous return. Meanwhile, these regions have strict patent protection, ensuring NG’s competitive advantage over 20 years. The product is currently at medical phase 0. R&D of additional 10-15 years with investment amounted to USD $1.5 billion is expected before launching. Once the product is clinically usable, NG will market the product to hospitals and treatment centers to sell off the solution priced at a medium level. NG only collects payment monthly based on the quantity the agents have sold out during that period, allowing NG to capture market share steadily by shifting the inventory risk away from the agents. Ideally, such a business model would generate USD 750 Mn revenue in the first year with CAGR at 20% in next 10 years and finally stabilizes at USD 4.6 Bn annually for additional 10 years at 30% margin. Considering burn rate of 200 million annually for 10 years, the IRR is 15%. However, the actual IRR may range from 10-20%. The Management Team of NG now constitutes of two postgraduate professionals in charge of technical solutions, three medical advisors with strong soft skills for pitching plus two business-side marketing and finance experts.
Views: 2671 LagtronicsURT
Solving radiotherapy s biggest limitation. Medicine is now using physics every day to treat cancer patients. Nanotechnologies or Nanomedicine can help clinicians deliver safer and more efficient treatments by shifting the intended effect from the macroscopic to the subcellular level. www.nanobiotix.com www.laurentlevy.com
Views: 115979 Laurent L
NanoMission - NanoMedicine Module : Take control as a biomedical scientist! Help to cure cancer through observation and experimentation by building nanoscopic particles and measuring their effects on the patient at the cellular level. Visit http://www.nanomission.org to Download the game!
Views: 27152 PlayGen Ltd
More about exceptional inventors and the European Inventor Award here: http://buzz.mw/b1zgp_l European Patent Office Europäisches Patentamt L'Office Européen des Brevets www.epo.org
Views: 3489 EPOfilms
South Korea scientists have developed nano-robots that can detect and treat cancer cells. The robot is a genetically modified bacterium only 20 microns in diameter. By delivering drugs directly to the tumor, it attacks the cancer while leaving healthy cells alone, sparing the patient from the side effects of chemotherapy. The treatment is expected to be put into medical use in five years. Subscribe to us on Youtube: https://goo.gl/lP12gA Download for IOS: https://itunes.apple.com/us/app/cctvnews-app/id922456579?l=zh&ls=1&mt=8 Download for Android: https://play.google.com/store/apps/details?id=com.imib.cctv Follow us on: Facebook: https://www.facebook.com/cctvnewschina Twitter: https://twitter.com/CCTVNEWS Google+: https://plus.google.com/+CCTVNEWSbeijing Tumblr: http://cctvnews.tumblr.com/ Weibo: http://weibo.com/cctvnewsbeijing
Views: 8244 CGTN
targeted drug delivery cancer pain benefits fy16 01 27 1
The vast majority of heart attacks occur when there is a sudden rupture of plaques, so-called vulnerable plaques, forming clots that can cause blockages in coronary arteries. The objective of the researchers' work was to develop a computational tool-set to support the design and analysis of a catheter-based local nanoparticulate drug delivery system to treat vulnerable plaques and diffuse atherosclerosis. The goal is to rationally design drug-encapsulated nanoparticles in conjunction with patient-specific attributes and deliver drug locally to the diseased arteries, thereby personalizing and optimizing therapeutic intervention. To that end, a three-dimensional mathematical model of coupled transport of drug and drug-encapsulated nanoparticles was developed and solved numerically utilizing isogeometric finite element analysis using the Texas Advanced Computing Center's (TACC) HPC resources. The visualization component of this project, a 14 minute animation, seeks to explain the motivation of the research, the physical mechanism of the proposed solution concept, the mathematical models used, the computational methodology applied for simulation, and the scientific visualization of the results. Researchers Shaolie Hossain, PhD Institute for Computational Engineering and Sciences (ICES) The University of Texas at Austin Thomas J. R. Hughes, PhD Institute for Computational Engineering and Sciences (ICES) The University of Texas at Austin Visualization and video production Ben Urick Texas Advanced Computing Center (TACC) The University of Texas at Austin Jo Wozniak Texas Advanced Computing Center (TACC) The University of Texas at Austin Erik Zumalt Faculty Innovation Center (FIC) The University of Texas at Austin Audio recording and post-production Juan Diaz Faculty Innovation Center (FIC) The University of Texas at Austin Chris Nungary Independent Audio Engineer
Views: 10252 TACCutexas
Medicines do not simply enter the body and wander around until they finds something to cure, and getting compounds to their intended target is one of the biggest challenges for drug manufacturers. The virtual lab in NanoMission V2 allows you to go from the organ view down to individual cells, analyzing the cells compositions, traveling down the blood stream and seeing the medicine you've created in action.
Views: 10647 PlayGen Ltd
Newest concept of drug dilevery system (nano prticles of drugs) for treatment of cancer.
Views: 6167 kulachi2011
Chemotherapy treats many types of cancer effectively. But it often causes side effects. Side effects happen when chemotherapy damages healthy cells. Professor Killugudi Swaminatha Iyer's team at UWA are developing nano-sized particles for targeted delivery of therapeutics to single cells for therapy and diagnostics.
When fighting cancer, speed is of the utmost importance. A microfluidic chip developed by Michigan engineers has enabled a breakthrough in testing the efficacy of specialized cancer drugs. This means getting the right drug to the right patient in a fraction of the time. These chips could make a huge difference in how fast we can develop a new drug or nanodrug. Until recently, a cancer drug lab screening could test ten variables in one day. A new microfluidic chip developed by Michigan engineers can now test one thousand different variable in one hour. This allows doctors to more quickly identify the best treatment for the individual patient based on their type of cancer and biology. These chips are especially useful for testing photodynamic cancer treatments in which drugs are only activated when exposed to light. This kind of hyper localized cancer treatment reduces the negative side effects of other options, like chemotherapy. ABOUT THE PROFESSORS: Euisik Yoon is a Professor in both the Electrical Engineering and Computer Science and Biomedical Engineering departments at the University of Michigan’s College of Engineering. Professor Yoon is also the director of the Solid-State Electronics Laboratory and the Lurie Nanofabrication Facility. His research focuses on MEMS, integrated microsystems, and VLSI circuit design. Raoul Kopelman, Professor of Chemistry, Physics, Applied Physics, and the Biomedical Engineering departments at the University of Michigan. His research focuses on Autonomous Nano-Devices for Biomedical Applications
Views: 3474 Michigan Engineering
This video explains the concept of so-called 'targeted' cancer drugs, built from a fundamental undertanding of the shape and function of the faulty molecules inside cancer cells. Find out more about our work on cancer drugs here: http://bit.ly/1DfoCuq and read about how faults in the BRAF gene were linked to cancer by Cancer Research UK-funded scientists on our blog: http://bit.ly/1L77hbt
Views: 8625 Cancer Research UK
SILVER SPRING, MARYLAND— A panel of experts advising the U.S. Food and Drug Administration has unanimously recommended the approval of a new cancer drug from pharmaceutical giant Novartis. The drug would be used to treat people suffering from leukemia. The New York Times reports that tisagenlecleucel is a gene therapy drug used to treat a blood cancer known as B-cell acute lymphoblastic leukemia in patients aged 3 to 25. The drug uses chimeric antigen receptor T-cell therapy, which reprograms immune cells to defeat cancer. The treatment first extracts a patient's own T-cells, then genetically modifies them using tisagenlecleucel to grow new receptors. These receptors target CD19, a protein expressed by malignant B-cells. Copies of the new cells are grown in the lab by the millions and injected back into the patient, where they then attack the cancer cells. In one test, the treatment led to complete remission in 83% of 52 patients. But it has potentially deadly short-term side effects, such as high fevers, low blood pressure, and lung problems. It's unclear what the long-term side effects are, if any. Therefore, patients who received treatment are recommended to be monitored for 15 years. The FDA will likely decide whether or not to approve the Novartis drug in the next few months. If they do, it will be the first gene therapy drug of its kind to hit the U.S. market. ------------------------------------------------------------- Go to https://www.patreon.com/tomonews and become a Patron now TomoNews is now on Patreon and we've got some cool perks for our hardcore fans. TomoNews is your best source for real news. We cover the funniest, craziest and most talked-about stories on the internet. Our tone is irreverent and unapologetic. If you’re laughing, we’re laughing. If you’re outraged, we’re outraged. We tell it like it is. And because we can animate stories, TomoNews brings you news like you’ve never seen before. Visit our official website for all the latest, uncensored videos: http://us.tomonews.com Check out our Android app: http://bit.ly/1rddhCj Check out our iOS app: http://bit.ly/1gO3z1f Get top stories delivered to your inbox everyday: http://bit.ly/tomo-newsletter See a story that should be animated? Tell us about it! Suggest a story here: http://bit.ly/suggest-tomonews Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus -~-~~-~~~-~~-~- Please watch: "Crying dog breaks the internet’s heart — but this sad dog story has a happy ending" https://www.youtube.com/watch?v=4prKTN9bYQc -~-~~-~~~-~~-~-
Views: 10504 TomoNews US
Katie Whitehead, assistant professor of chemical engineering, is “killing cancer from the inside, out.” She discusses her nanoparticle drug delivery research in this video.
This animation describes the latest research developments in nanoparticle-based cancer therapies. It explores how the technology can be used to specifically target cancer cells over healthy cells and how scientists can exploit the natural processes of cells to deliver the drug inside the cell where it is needed for its cancer-killing effect. CREDITS This animation was created by UNSW's 3D Visualisation Aesthetics Lab and was informed by the scientific imaging and cancer research of UQ IMB's Professor Rob Parton and his team. Their combined efforts are part of the research activities of the ARC Centre of Excellence in Bio-Nano Science and Technology. For more information please visit http://www.bionano.org.au.
Views: 252 Institute for Molecular Bioscience
A new drug delivery system for the selective treatment of colorectal tumor cells.
Views: 128 UABResearchPark
Check out our official website: http://us.tomonews.net/ Check out our Android app: http://goo.gl/PtT6VD Check out our iOS app: http://bit.ly/1gO3z1f ------------------------------------------------------------------------------------------------ A new blood cancer drug, a potential alternative to the common chemotherapy drug melphalan but with fewer side effects, has passed a crucial mid-stage trial, according to a Reuters report. The new drug Captisol-enabled melphalan developed by the U.S.-based Spectrum Pharmaceutical does not contain propylene glycol, a chemical believed to be responsible for the side effects of chemotherapy, such as renal and cardiac failure. The injectable drug is now being tested in patients with multiple myeloma undergoing stem cell transplants. Multiple myeloma is a form of blood cancer caused by the proliferation of cancerous plasma cells. As such malignant cells multiply, the normal blood cells will be crowded out. Around 22,000 cases of multiple myeloma are diagnosed in the United States each year. ------------------------------------------------------------------------------------------------ Welcome to TomoNews, where we animate the most entertaining news on the internets. Come here for an animated look at viral headlines, US news, celebrity gossip, salacious scandals, dumb criminals and much more! Subscribe now for daily news animations that will knock your socks off. Check out our Android app: https://play.google.com/store/apps/details?id=com.nextmedia.gan Check out our iOS app: https://itunes.apple.com/app/tomonews/id633875353 For news that's fun and never boring, visit our channel: https://www.youtube.com/user/TomoNewsUS Subscribe to stay updated on all the top stories: https://www.youtube.com/channel/UCt-WqkTyKK1_70U4bb4k4lQ?sub_confirmation=1 Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus -~-~~-~~~-~~-~- Please watch: "Crying dog breaks the internet’s heart — but this sad dog story has a happy ending" https://www.youtube.com/watch?v=4prKTN9bYQc -~-~~-~~~-~~-~-
Views: 17171 TomoNews US
Nanotechnology and personalized medicine are combined to provide hope for those suffering from cancer. Learn how Prof. Avi Schroeder and his team in the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies in the Wolfson Faculty of Chemical Engineering at Technion-Israel Institute of Technology have done it.
Views: 10011 Technion
UAlberta professor Afsaneh Lavasanifar uses nanotechnology to target medicine delivery and improve drug absorption. Primarily focused on chemotherapy drugs, which can be harmful to organs like the heart and kidneys, she's developed a patented polymer technology that can carry medicines to targeted areas—delivering medicine directly to a tumour and away from surrounding healthy tissues. The result—better, more effective medicine with less side-effects.
Views: 912 UniversityofAlberta
► Magnet-based drug delivery system shows promise for cancer treatment ► Magnet-based drug delivery system shows promise for cancer treatment Andrey Zakharchenko, a doctoral... ► Subscribe:https://goo.gl/edZWjG ► Photo & Content Source :https://goo.gl/3E5fAf ========================================= ► Health & Prevention Channel dedicated to sharing the latest news around the world. ► Videos can use content-based copyright law contains reasonable use Fair Use (https://www..com/yt/copyright/). ► With the above criteria, if there is any breach of the principles of Community, law on copyright then please comment on the video.
Views: 6 THE ROYALS FAMILY
ROCKVILLE, Md., July 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it was issued patent number 5749273 from the Japanese Patent Office entitled "Polymeric Systems for the Delivery of Anticancer Drugs" for the Company’s novel CPMA drug delivery platform. This new CPMA drug delivery platform technology, developed by Rexahn, enables more precise, targeted delivery of anti-cancer drugs directly into cancer cells. “There is a significant unmet need in the oncology field for drugs which selectively target and kill cancer cells while sparing normal, healthy cells. By utilizing our proprietary CPMA polymer drug delivery technology and combining it with currently approved anti-cancer drugs, we hope to transport anti-cancer drugs directly into cancerous cells where their cytotoxic activity can be most effective, thereby increasing efficacy and minimizing the harmful side effects associated with traditional cancer therapy,” said Dr. Peter D. Suzdak, Chief Executive Officer. “Rexahn Pharmaceuticals is pleased to be at the forefront of the development of novel, targeted approaches to cancer treatment, which could yield meaningful improvements in quality of life for cancer patients.” Dr. Suzdak continued, “Rexahn remains committed to ensuring the strongest possible intellectual property protection for our proprietary anti-cancer programs and platform technologies. We are pleased to be issued this latest patent, which expands our intellectual property estate and extends intellectual property protection for the CPMA platform.” About Rexahn's Proprietary CPMA Drug Delivery Platform CPMA is a polymer based drug delivery platform for the targeted delivery of anti-cancer compounds directly to cancer cells. The highly versatile chemical properties of CPMA allow it to be covalently linked to a diverse range of anti-cancer compounds together with a signaling moiety directing it to cancer cells and bypassing healthy tissues. Once inside a cancer cell, the covalent linker is metabolized yielding the free anti-cancer compound. CPMA has the flexibility to covalently bind multiple anti-cancer compounds into a single formulation. Because it is highly water soluble, CPMA also enables compounds that are water insoluble to be more effectively delivered and bioavailable.
Views: 182 CorporateProfile
The short video describes how Dr. Sudipta Basu and his team of researchers from IISER Pune, used drug transporting Nanoparticles to target the Mitochondria (Power House of Cell) of Cancer Cells for Next-Generation Therapeutics. Production: Science Media Centre, IISER Pune Research and Script: Sudipta Basu, Abhik Mallick Crew: Vivek Kannadi, Parmeswar Singh Yadav Music: http://www.bensound.com Science Media Centre, IISER Pune: https://sites.google.com/acads.iiserpune.ac.in/smc/home IISER Pune has established the Science Media Centre to foster and strengthen science communication. We produce high quality media to communicate science through popular science films, research highlights and documentaries. The Science Media Centre conducts workshops to train personnel in print and electronic media to encourage science communication. We also archive science related events and activities of the institute.
Views: 1593 IISER Pune
ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, “Polymeric Systems for the Delivery of Anticancer Drugs”. The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn. “We are pleased to further expand our platform of proprietary drug delivery technologies in preclinical development. CPMA complements our nano-polymer-drug delivery platform, nano-polymer-drug conjugate system (NPDCS), which has already shown promising results in preclinical studies,” stated Rexahn’s CEO, Peter D. Suzdak, Ph.D. “Our drug delivery platforms address a well-recognized need in cancer treatment for drugs that selectively target and kill cancer cells, while leaving healthy cells unharmed. Although numerous widely used FDA-approved anti-cancer drugs offer benefits to patients, in most cases, the efficacy of these drugs can be significantly improved, and their toxic side-effects minimized, if they can be combined with a targeted drug delivery technology to bring the drug directly into cancer cells.” The CPMA technology platform allows for multiple anti-cancer compounds to be covalently bound to the proprietary polymer backbone and be coupled to a signaling moiety. The signaling moiety directs the bound drug to the cancer cell, thereby bypassing healthy cells leading to enhanced efficacy with the potential for reduced side effects. Once inside the cancer cell the CPMA complex is metabolized yielding the free anticancer compound. Because of its diverse chemical properties, CPMA is highly water soluble which allows water insoluble anti-cancer compounds to be bioavailable through a more effective delivery.
Views: 295 CorporateProfile
More about exceptional inventors and the European Inventor Award here: http://buzz.mw/b1zgp_l European Patent Office Europäisches Patentamt L'Office Européen des Brevets www.epo.org
Views: 614 EPOfilms
(Visit: http://www.uctv.tv/) Tejal Desai, Professor, Department of Bioengineering and Therapeutic Sciences, explores the future of targeted drug delivery through minute nano-engineered devices Series: "UCSF Osher Mini Medical School for the Public" [7/2012] [Health and Medicine] [Show ID: 23804]
Views: 16188 University of California Television (UCTV)
Recently a Food and Drug Administration panel unanimously recommended the agency approve a cutting-edge cancer therapy. One expert called it the “most exciting thing I’ve seen in my lifetime.” So what is it? CAR T-cell treatment is a process where millions of a patient’s T-cells are removed and genetically engineered. These new T-cells capable of killing thousands of cancer cells, and a single turbocharged cell can destroy up to 100,000 cells.
Views: 321 The Spoke
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found. Their research gives oncologists a better shot at overcoming the problems of drug resistance, toxicity to patients and a host of other barriers to consistently achieving successful gene therapy for cancer. It is particularly promising for patients with triple-negative breast cancer, an aggressive type that makes up about 15-20 percent of cases. Craig Duvall, associate professor of biomedical engineering, put the effectiveness of a specialized ribonucleic acid hitchhiking on the human protein albumin up against jetPEI nanoparticles, the mostly widely used synthetic carrier for the task of tumor gene silencing. His findings, reached with Samantha Sarett, a recent biomedical engineering Ph.D. graduate, are published today (Monday, July 24) in the Proceedings of the National Academy of Sciences. Albumin is ‘Trojan horse’ Ribonucleic acids can control the behavior of cancer cells, but they require a carrier to get them to the target. Duvall’s team made a simple modification to a small-interfering ribonucleic acid molecule, called siRNA-L2, allowing it to rapidly load into an albumin pocket typically reserved to ferry fatty acids around the body. They found that the siRNA-L2, using albumin as its carrier, has no apparent dose-limiting toxicity, a significant problem for synthetic nanoparticles. That means a higher dose of the anti-cancer drug can be delivered to the tumor without potentially harming the patient. "Albumin serves almost like a Trojan Horse where it carries it throughout the blood keeps it in the bloodstream for a longer period of time," said Duvall. “We used albumin because it’s the highest-concentrated protein in your blood,” he said. “Our molecule, siRNA-L2, binds into the fatty acid pocket of albumin. If we put siRNA directly into the body without a carrier, it’s cleared out by the kidneys in two minutes. If we load siRNA into synthetic nanoparticles to avoid that, then they’re filtered out by the liver. Albumin circulates in the body for days, making the siRNA-L2 molecules more available for delivery into tumors.” Because cancer cells show higher metabolic activity, the albumin that’s carrying siRNA-L2 travels to tumors and gets to work quickly. The molecule’s smaller size allows it to penetrate tumors at a higher rate – with 100 percent of tumor cells testing positive for siRNA-L2 as opposed to only 60 percent when the molecule was carried by jetPEI. Once there, Duvall’s molecule silences a gene crucial to the tumor’s growth and survival. He said he used the synthetic carrier as a comparison because polymer-based jetPEI represents the gold standard available. Tested on human tissue To make sure their results were translatable to human therapy, the team – in collaboration with Vanderbilt University Medical Center cancer biologist Dana Brantley-Sieders -- tested siRNA-L2 in human breast tumor tissue removed from the donor. The Vanderbilt molecule remained more effective, with siRNA-L2 more than three times as present in the tumor than siRNA delivered with synthetic nanoparticles. Brantley-Sieders said their research has the potential of overcoming the biggest barriers to clinical application of gene-silencing ribonucleic acids. “What fascinates and excites me most about this approach, in addition to improved tumor penetration, is lack of toxicity at a relatively high dose,” she said. “We could potentially use our siRNA delivery system to target several genes simultaneously or sequentially. Most cancers are driven by multiple abnormal genes, so targeting one often leads to activation of others as the tumor adapts.” Funding for the research is through the National Institutes of Health and the National Science Foundation. Media Inquiries Heidi Hall, (615) 322-NEWS Heidi.Hall@Vanderbilt.edu Follow Vanderbilt on Twitter: https://twitter.com/vanderbiltu, on Instagram: http://instagram.com/vanderbiltu and on Facebook: https://www.facebook.com/vanderbilt. See all Vanderbilt social media at http://social.vanderbilt.edu.
Views: 209 Vanderbilt University
Nanotechnology, the manipulation of matter at the atomic and molecular scale to create materials with remarkably varied and new properties, is a rapidly expanding area of research with huge potential in many sectors, ranging from healthcare to construction and electronics. In medicine, it promises to revolutionize drug delivery, gene therapy, diagnostics, and many areas of research, development and clinical application. The field of medicine is taking its first steps towards patient-specific care. Research is aimed at tailoring treatments to address each person’s individualized needs and unique disease presentation. Scientists are developing nanoparticles that target disease sites, where they perform a programmed therapeutic task. These systems utilize molecular-machines and cellular recognition to improve efficacy and reduce side effects. --------- Facebook: https://www.facebook.com/agingreversed Twitter: https://twitter.com/Aging_Reversed Support the Channel: https://goo.gl/ciSpg1 Channel t-shirt: https://teespring.com/aging-reversed
Views: 807 Aging Reversed
A new discovery by the Regulatory Biology Laboratory at The Salk Institute, led by Prof. Beverly Emerson and Staff Scientist Fernando Lopez-Diaz, reveals how cancer is able to resist drug therapies and grow back, hopefully leading to more targeted pharmaceutical treatments.
Views: 2982 Salk Institute
Oncologist Stephen Lemon MD describes targeted therapy for cancer treatment and how it compares to standard chemotherapy. Visit http://www.canceris.net/targeted-cancer-therapy-work/ to learn more about his discussion on targeted therapy. Transcript of Dr. Stephen Lemon talk on targeted cancer therapy: "Targeted cancer therapy is a new and very promising approach to the treatment of cancer. It is designing new treatments, new drugs, that specifically target the cancer cell, so they avoid regular cells and go directly to the cancer cell and the cause that cancer cell to die. It includes drugs such as Herceptin, Avastin, and Erbitux. These can be given by themselves, or in combination with regular chemotherapy. He said that this drug would go direct to the cancer in the colon, and I said, “well, does it have a GPS or something to know where to go or something, it mustn't dilly-dally!” He explained it as a smart bomb, which was a great way of explaining it, he said it's gonna go in there and it's gonna kill every HER2/neu positive protein that you've got. The Avastin's looking for those cells that hide, you know, they're lurking there, that's what the Avastin does, it's a follow-up. It's a clean-up, so to speak. Targeted therapies are specific to individual cancers, so different targeted therapies are used in different cancer treatments. Dr. Lemon put me on Herceptin because it's a blocker, it'll keep the kind of cancer that I had from coming back is the way it was explained to me. So I would come in once a week for exactly a year and get the injections. It didn't really phase me at all. Common side effects in regular chemotherapy, such as hair loss, nausea, vomiting, are the result of cancer treatment going to normal cells, such as hair follicles and cells of the intestinal tract. But targeted therapy, because it zeroes in on specific cancer cells, avoids those side effects, so someone does not lose their hair or have a lot of nausea or vomiting. Well, I don't know what drugs he had me on, but he had me on it in June, and that was my lowest ebb, was in June. I just wasn't doing well, I had diarrhea, that was the worst thing to have to handle because I was getting to the point where I was almost housebound. So he switched me over to Erbitux, and that has been just night and day. The diarrhea has stopped, but a side effect was breaking out of the face, and I said well that I could handle, with a little liquid makeup I'm fine. But to be able to go and shop and not have my other problem, it's a relief. Now sometimes when the targeted therapy is combined with traditional chemotherapy, a patient will still have those side effects. From the Herceptin itself I didn't have any side effects. I did lose my hair, it wasn't from the Herceptin, it was from the chemo drugs, my chemo cocktail I call it. Evidently this drug is working, I'm feeling much better, I'm feeling better than I've felt in a year. If you're not going through treatment you have no reason to know what HER2/neu positive is, and what Herceptin is, and how new and amazing Herceptin is, you just have no idea."
Views: 10116 CancerIS
Tayebeh Anajafi Marzijarani, 2017 North Dakota State University Three Minute Thesis (3MT) competition champion, talks about her research on targeted drug delivery for pancreatic cancer.
Views: 343 North Dakota State University
New "smart" material could automatically deliver your medication inside your body without a reminder. More information on this story at http://www.insidescience.org/content/smart-drug-delivery-system/1618. Additional content at http://www.insidescience.org/.
Views: 6944 Inside Science
Visit us at http://www.VisualSonics.com/VideoWorkshops to watch this video and other preclinical research presentations in entirety. Presented by: Kenneth P. Olive Columbia University Herbert Irving Comprehensive Cancer Center Departments of Medicine and Pathology seo strategy keywords pancreatic cancer pancreas ultrasound imaging ultrasound micro-ultrasound high-frequency preclinical imaging biology research mouse cancer visualsonics visual sonics
Views: 835 VisualSonics